Pharma BD Deal Intelligence
A $5.3B asset sale that let Novartis add Xiidra to its ophthalmology portfolio while Takeda used the proceeds to pay down debt from its Shire acquisition. The dry-eye drug's modest post-deal trajectory made this more debt-relief maneuver than growth engine for either side.
Takeda completed the sale of Xiidra to Novartis to accelerate deleveraging following its $62 billion acquisition of Shire, transferring approximately…
Novartis completed the divestment of its front-of-eye ophthalmology assets (including Xiidra/lifitegrast and SAF312/libvatrep) to Bausch + Lomb on September…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Novartis acquired global rights to Xiidra (lifitegrast), an approved treatment for dry eye disease, from Takeda (which inherited the asset from its Shire acquisition). Novartis paid $3.4B upfront plus up to $1.9B in milestones. This was part of Takeda's post-Shire divestiture strategy to reduce debt.
Chronic Ocular Surface Pain has no FDA-approved on-label pharmacotherapy. Off-label treatments include oral gabapentinoids (gabapentin, pregabalin), autologous serum tears, and compounded topical drops. Investigational: SAF312 (libvatrep, Novartis; TRPV1 antagonist, Phase 2 for chronic ocular pain); XG-102 (c-Jun inhibitor); various neuropathic-pain platforms. Novartis acquired the SAF312 program from Shire via Takeda divestiture. The competitive field is largely investigational; no branded comparator franchise exists for commercial-lead sizing.
Dry eye disease (DED) is a crowded topical ophthalmic market stratified across four distinct MOA classes, each with branded and generic pressure. Calcineurin inhibitors: Restasis (cyclosporine 0.05% ophthalmic emulsion, AbbVie/Allergan, FDA-approved December 2003) is the category-defining product, with authorized generics eroding brand share since 2020; Cequa (cyclosporine 0.09% nanomicellar, Sun Pharma, approved August 2018) and Verkazia (cyclosporine 0.1%, Santen, approved for vernal keratoconjunctivitis) compete on formulation differentiation. LFA-1 antagonists: Xiidra (lifitegrast 5% ophthalmic solution, Novartis, approved July 2016) is the only approved agent in this class; Novartis reported Xiidra net sales of approximately $491M in FY2023. Tear-film stabilizers / semifluorinated alkanes: Miebo (perfluorohexyloctane ophthalmic solution, Bausch + Lomb/Novaliq, FDA-approved May 2023) targets evaporative DED via tear-film stabilization and is the fastest-growing new entrant. Neurostimulation / novel mechanisms: Tyrvaya (varenicline solution nasal spray, Viatris/Oyster Point, approved October 2021) stimulates trigeminal parasympathetic pathway to drive natural tear production; Eysuvis (loteprednol etabonate 0.25% ophthalmic suspension, Kala Pharmaceuticals, approved October 2020) serves short-course flare management. Commercial read: Restasis genericization plus Miebo launch compress Xiidra's pricing power; Tyrvaya's non-topical route and Miebo's novel evaporative MOA are the structural threats Novartis must counter through chronic-use adherence messaging and IP defense.
Novartis to acquire Xiidra from Takeda for $3.4B upfront + $1.9B milestones. Part of Novartis AG's $5.3B deal to acquire Takeda Pharmaceutical Co. Ltd..
Novartis AG completed its acquisition of Takeda Pharmaceutical Co. Ltd. for $5.3B. Novartis acquired global rights to Xiidra (lifitegrast), an approved treatment for dry eye disease, from Takeda (which inherited the asset from its Shire acquisition).
EMA raised major objections; European approval path abandoned. Regulatory step in Novartis AG's acquisition process for Takeda Pharmaceutical Co. Ltd..
Divested Xiidra and ophthalmology assets, recouping ~74% of upfront cost. Part of Novartis AG's $5.3B deal to acquire Takeda Pharmaceutical Co. Ltd..
See timeline for full assessment. Assessment of Novartis AG's $5.3B acquisition of Takeda Pharmaceutical Co. Ltd. and its strategic outcomes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Takeda Pharmaceutical Company Ltd. (this deal) | 2019 | $5.3B | 33 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2019 deals · Novartis AG deals · Neurology deals